TARS vs AEYE vs LNTH vs ALKT vs NUVL

For growth investors, Tarsus Pharmaceuticals, Inc.

(TARS) is the stronger pick with 146. 7% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Tarsus Pharmaceuticals, Inc. (TARS) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Lantheus Holdings, Inc.

is actually cheaper at 17. 5x.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +446. 1%, compared to -60. 2% for AudioEye, Inc. (AEYE). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus ALKT's -59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 387% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 98% for Alkami Technology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Tarsus Pharmaceuticals, Inc.

(TARS) is pulling ahead at 146. 7% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Tarsus Pharmaceuticals, Inc. grew EPS 48. 2% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Over a 3-year CAGR, TARS leads at 159. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -14. 7% for Tarsus Pharmaceuticals, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -15. 7% for TARS. At the gross margin level — before operating expenses — TARS leads at 93. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Lantheus Holdings, Inc.

(LNTH) trades at 17. 5x forward P/E versus 21. 7x for Alkami Technology, Inc. — 4. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUVL: 41. 0% to $144. 40.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). AudioEye, Inc. (AEYE) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNTH: +41. 9%, AEYE: +102. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TARS (Healthcare) and AEYE (Technology) and LNTH (Healthcare) and ALKT (Technology) and NUVL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TARS is a small-cap high-growth stock; AEYE is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; ALKT is a small-cap high-growth stock; NUVL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.